Search

Displaying 2 news results

• 

  Dec 3, 2020

  Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-Stage Age-Related Macular Degeneration

  Acquisition significantly expands Janssen’s eye disease portfolio and strengthens its gene therapy capabilities. Late-stage AMD affects millions of people with no effective treatments currently available .

  Partner News
• 

  May 27, 2020

  Abfero Targeting Excess Iron to Treat AMD, Other Retinal Diseases

  An intriguing link between excess body iron and retinal degeneration is being explored by Abfero Pharmaceuticals, a young biotech based in Boston and Oxford, UK.

  Partner News